Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 3/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | TERT | O14746 | 2/20 | 0.52 |
| ▸ | DTYMK | P23919 | 4/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.49 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.47 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31276800 | 1.00 | P2RY2 (0.56) | P2RY2P2RY4P2RY6POLBF2 | |
| SCHEMBL29551577 | 1.00 | P2RY2 (0.56) | P2RY2P2RY4P2RY6POLBF2 | |
| SCHEMBL23071689 | 0.96 | P2RY2 (0.53) | P2RY2P2RY4P2RY6POLBF2 | |
| SCHEMBL23071682 | 0.96 | P2RY2 (0.53) | P2RY2P2RY4P2RY6POLBF2 | |
| SCHEMBL23071694 | 0.96 | P2RY2 (0.53) | P2RY2P2RY4P2RY6POLBF2 | |
| SCHEMBL30839331 | 0.96 | P2RY2 (0.57) | P2RY2P2RY4P2RY6POLBF2 | |
| SCHEMBL29551697 | 0.95 | P2RY2 (0.61) | P2RY2P2RY4P2RY6POLBF2 | |
| SCHEMBL29365163 | 0.95 | P2RY2 (0.61) | P2RY2P2RY4P2RY6POLBF2 | |
| SCHEMBL8614074 | 0.94 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBF2 | |
| SCHEMBL8613676 | 0.94 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497609-B2 | Protospacer adjacent motif sequence and method for modifying target nucleic acid in genome of cell by using same | YONSEI UNIVERSITY BIOHEALTH TECHNOLOGY HOLDINGS. INC. (KR) | 2025-12-16 | — | — | US | claimed |
| US-20250019739-A1 | EXONUCLEASE-COUPLED REAL-TIME ENDONUCLEASE ACTIVITY ASSAY | CARIBOU BIOSCIENCES, INC. (US) | 2025-01-16 | — | — | US | claimed |
| CN-114555803-B | Novel prosomain sequence adjacent motif sequences and methods of using the same for modifying target nucleic acids in cellular genomes | 延世大学校产学协力团 | 2024-11-29 | — | — | CN | claimed |
| US-20240384268-A1 | Oligonucleotides | Hudson Institute of Medical Research (AU) | 2024-11-21 | — | — | US | claimed |
| EP-4423502-A1 | EXONUCLEASE-COUPLED REAL-TIME ENDONUCLEASE ACTIVITY ASSAY | Caribou Biosciences, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| WO-2024099575-A1 | ARTIFICIAL NUCLEIC ACIDS FOR SITE-DIRECTED EDITING OF A TARGET RNA | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2024-05-16 | — | — | WO | claimed |
| CN-117999481-A | Exonuclease coupled real-time endonuclease activity assay | 卡里布生物科学公司 | 2024-05-07 | — | — | CN | claimed |
| EP-4320237-A1 | OLIGONUCLEOTIDES | Hudson Institute of Medical Research (AU) | 2024-02-14 | — | — | EP | claimed |
| CN-117043340-A | Oligonucleotides | 哈德森医学研究所 | 2023-11-10 | — | — | CN | claimed |
| WO-2023097268-A2 | EXTRACELLULAR VESICLES COMPRISING NON-NATURALLY OCCURRING MODULAR RNA HAIRPINS AND USES THEREOF | MANTRA BIO, INC. (US) | 2023-06-01 | — | — | WO | claimed |
| WO-2023075154-A1 | METHOD FOR INACTIVATING GENE OF PORCINE ENDOGENOUS RETROVIRUS AND COMPOSITION THEREOF | 주식회사 툴젠 | 2023-05-04 | — | — | WO | claimed |
| WO-2023076857-A1 | EXONUCLEASE-COUPLED REAL-TIME ENDONUCLEASE ACTIVITY ASSAY | CARIBOU BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| US-20230074760-A1 | NOVEL PROTOSPACER ADJACENT MOTIF SEQUENCE AND METHOD FOR MODIFYING TARGET NUCLEIC ACID IN GENOME OF CELL BY USING SAME | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2023-03-09 | — | — | US | claimed |
| WO-2022213153-A1 | OLIGONUCLEOTIDES | Hudson Institute of Medical Research (AU) | 2022-10-13 | — | — | WO | claimed |
| CN-114555803-A | Prespacer sequence adjacent motif sequence and method for modifying target nucleic acid in cell genome by using the same | 延世大学校产学协力团 | 2022-05-27 | — | — | CN | claimed |
| US-20260109985-A1 | THERAPY BY TRANS-SPLICING OF OPA1 PRE-MESSENGER RNAS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OPA1 GENE MUTATIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2026-04-23 | — | — | US | disclosed |
| EP-3727435-B1 | BIVALENT NUCLEIC ACID LIGANDS AND USES THEREFOR | UNIV CARNEGIE MELLON (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2022213153-A1 | OLIGONUCLEOTIDES | Hudson Institute of Medical Research (AU) | 2022-10-13 | — | — | WO | disclosed |
| CN-115171783-A | Method and device for directed evolution of enzyme | 上海合全药业股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-114555803-A | Prespacer sequence adjacent motif sequence and method for modifying target nucleic acid in cell genome by using the same | 延世大学校产学协力团 | 2022-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109985-A1 | THERAPY BY TRANS-SPLICING OF OPA1 PRE-MESSENGER RNAS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OPA1 GENE MUTATIONS | OPA1, UPF1, POLRMT | P2RY2 4211/4885P2RY4 4679/4885P2RY6 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.